FIELD: immunology.
SUBSTANCE: present invention relates to immunology. There are presented humanised antibodies or their antigen-binding fragments selectively binding with shiga-like toxins of the first and/or second type and neutralizing them. What is also considered is a composition containing a mixture of the above antibodies.
EFFECT: present invention can find further application in therapy of toxic conditions caused by enterohaemorrhagic Escherichia coli.
6 cl, 1 tbl, 4 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| HUMANIZED ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2020 |
|
RU2804963C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| RECOMBINANT Fab-scFv BASED ON A NEUTRALISING ANTIBODY AGAINST HUMAN BETA-1A INTERFERON AND AN ANTIBODY AGAINST HUMAN ErbB2 RECEPTOR | 2019 |
|
RU2748953C1 |
| ANTIBODIES AGAINST FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND USE | 2011 |
|
RU2740479C2 |
| HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
| EphA4 ANTIBODY | 2016 |
|
RU2719158C2 |
| EphA4 ANTIBODY | 2020 |
|
RU2816371C2 |
| MONOCLONAL ANTIBODY TO NAV1.7 | 2019 |
|
RU2776821C2 |
